Health Care & Life Sciences » Pharmaceuticals | China Medical System Holdings Ltd.

China Medical System Holdings Ltd. | Income Statement

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,818
3,707
4,383
5,726
6,168
6,436
Cost of Goods Sold (COGS) incl. D&A
1,281
1,624
1,859
2,324
2,157
1,796
Gross Income
1,536
2,082
2,524
3,402
4,011
4,639
SG&A Expense
768
985
1,242
1,630
1,850
2,269
EBIT
768
1,141
1,318
1,772
2,161
2,370
Unusual Expense
10
271
-
23
-
20
Non Operating Income/Expense
71
13
9
55
121
57
Interest Expense
21
21
30
50
95
85
Pretax Income
858
1,422
1,291
1,696
1,996
2,278
Income Tax
63
109
83
143
160
192
Equity in Affiliates
1
1
21
57
90
98
Consolidated Net Income
796
1,313
1,229
1,610
1,926
2,185
Net Income
798
1,316
1,228
1,608
1,931
2,191
Net Income After Extraordinaries
798
1,316
1,228
1,608
1,931
2,191
Net Income Available to Common
798
1,316
1,228
1,608
1,931
2,191
EPS (Basic)
0.33
0.54
0.50
0.65
0.78
0.88
Basic Shares Outstanding
2,415
2,415
2,467
2,487
2,487
2,486
EPS (Diluted)
0.33
0.55
0.50
0.65
0.78
0.88
Diluted Shares Outstanding
2,415
2,415
2,467
2,487
2,487
2,486
EBITDA
814
1,195
1,414
1,977
2,388
2,606
Other Operating Expense
-
45
36
-
-
-
Non-Operating Interest Income
50
44
12
23
20
31
Minority Interest Expense
1
3
1
2
6
6

About China Medical System Holdings

View Profile
Address
6/F-8/F, Block B
Shenzhen Guangdong 518052
China
Employees -
Website http://www.cms.net.cn
Updated 07/08/2019
China Medical System Holdings Ltd. engages in the provision of pharmaceutical products and services. The company focuses on the manufacture, marketing, promotion, and sale of drugs. Its products include Plendi, XinHuoSu, Stulln, XiDaKang, YiNuoShu, DanShenTong, Hirudoid, NuoDiKang, Combizym, GanFuLe, Imdur, Parlodel, Lamisil, YinLianQingGan, and MOVICOL.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.